Survodutide: Burning Fat Faster Survodutide is different from Ozempic
Sergey Terushkin, MD, FACS, and Janna Goldfeld, PA-C, can review your previous treatment, symptoms, health history, and goals before discussing medically appropriate options
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
For comparisons of categorical variables, 2 tests were applied
For people transitioning specifically because of metabolic health concerns beyond weight, this distinction matters enormously
4.9%), exenatide (Byetta